CTOs on the Move


 
Seer is a life sciences and health data company focused on capturing and translating deep molecular insights from the proteome to enable early detection of cancer and neurological diseases, drive earlier treatment, and improve patient outcomes.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.seer.bio
  • 170 Harbor Way
    South San Francisco, CA USA 94080
  • Phone: 650.453.0000

Executives

Name Title Contact Details
Tracy Piner
Director, Digital Marketing Profile
Fabio Patino
Vice President of IT and Chief Information Security Officer Profile

Funding

Seer raised $36M on 12/17/2018
Seer raised $55M on 12/17/2019
Seer raised $55M on 07/22/2020

Similar Companies

TYME Inc

TYME is an emerging biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles.

Integral BioSystems

To transform research concepts from the lab to clinic-ready products.Integral BioSystems was founded by drug development experts with many years of combined expertise in pharmaceutics and the development of drug products. The company is based in the greater Boston area.

NationalAccessCannabis

We are dedicated to health and to working in consultation with health professionals. We are committed to responsibility, through our secure non-transferable medical cannabis access card system. A system we are establishing in consultation with law enforcement to achieve national recognition.

Dendritic NanoTechnologies

Dendritic NanoTechnologies, Inc. is a Mount Pleasant, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bicycle Therapeutics

Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycles attractive candidates for drug development. Bicycle is evaluating BT5528, a second-generation Bicycle Toxin Conjugate (BTC™) targeting EphA2; BT8009, a second-generation BTC targeting Nectin-4, a well-validated tumor antigen; and BT7480, a Bicycle TICA™ targeting Nectin-4 and agonizing CD137, in company-sponsored Phase I/II trials. In addition, BT1718, a BTC that targets MT1-MMP, is being investigated in an ongoing Phase I/IIa clinical trial sponsored by the Cancer Research UK Centre for Drug Development. Bicycle is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Lexington, MA.